Genmab ADR(GMAB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 18 at 7:30 PM ET (Korea 9/19 08:30)
Full metrics table
| Index | - | P/E | 27.51 | EPS (ttm) | 1.26 | Insider Own | 1.75% | Shs Outstand | 597.0M | Perf Week | 6.99% |
| Market Cap | 20.76B | Forward P/E | 20.1 | EPS next Y | 45.04% | Insider Trans | - | Shs Float | 587.1M | Perf Month | 1.85% |
| Enterprise Value | 24.53B | PEG | 1.04 | EPS next Q | 0.38 | Inst Own | 15.56% | Short Float | 1.16% | Perf Quarter | 37.48% |
| Income | 0.79B | P/S | 5.03 | EPS this Y | -22.47% | Inst Trans | 0.28% | Short Ratio | 3.07 | Perf Half Y | 35.02% |
| Sales | 4.13B | P/B | 3.48 | EPS next 5Y | 19.42% | ROA | 8.28% | Short Interest | 6.83M | Perf YTD | 12.79% |
| Book/sh | 9.98 | P/C | 13.81 | EPS past 3/5Y | 9.68% 6.84% | ROE | 13.96% | 52W High | -1.95% ($35.43) | Perf Year | 23.89% |
| Cash/sh | 2.52 | P/FCF | 23.86 | Sales past 3/5Y | 22.11% 19.27% | ROIC | 7.2% | 52W Low | 47.08% ($23.62) | Perf 3Y | -7.09% |
| Dividend Est. | - | EV/EBITDA | 17.2 | EPS Y/Y TTM | -36.69% | Gross Margin | 93.03% | Volatility(W/M) | 2.32% 1.96% | Perf 5Y | -19.43% |
| Dividend TTM | - | EV/Sales | 5.94 | Sales Y/Y TTM | 21.75% | Oper. Margin | 32.27% | ATR (14) | 0.79 | Perf 10Y | 112.97% |
| Dividend Ex-Date | - | Quick Ratio | 2.44 | EPS Q/Q | -11.45% | Profit Margin | 19.04% | RSI (14) | 64.68 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.46 | Sales Q/Q | 23.03% | SMA20 | 3.34% ($33.62) | Beta | 0.82 | Target Price | $39.17 |
| Payout | - | Debt/Eq | 0.89 | Earnings | 2026/8/6 | SMA50 | 10.61% ($31.41) | Rel Volume | 1.22 | Prev Close | $34.53 |
| Employees | 3029 | LT Debt/Eq | 0.83 | EPS/Sales Surpr. | 37.92% 3.46% | SMA200 | 17.94% ($29.46) | Avg Volume(3M) | 2.22M | Price | $34.74 |
| IPO | 2009/6/1 | Option/Short | Yes/Yes | Trades | 18005 | Volume | 2,711,562 | Change | 0.59% |
Company
GMAB is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A Denmark-based biotech company specializing in antibody therapeutics. Leveraging its proprietary antibody technology platform, it develops anticancer antibody drugs and generates revenue through collaborations with multinational pharmaceutical companies as well as its own in-house drug products, positioning it as a global antibody therapeutics company.
Over the past 1 year, on the higher side
2% below its 1-year high.
GMAB makes money exceptionally well
32.27% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -22.5% this year.
Tap to view numbers
The price looks about right
Trading at 27.5 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -7.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 15.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FBT 0.03%
CANC 0.02%
AADR 0.02%
IBB 0.01%
WDNA 0.00%It ranks #4 in the industry
Based on market cap of $21B.
GMAB $21B PER 27.5
VRTX $129B PER 29.6
REGN $81B PER 19.4
ARGX $62B PER 37.7
FAQ
What kind of company is GMAB?
GMAB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GMAB?
The market cap of GMAB is approximately $20.8B, ranking 590 within its sector.
What is the P/E ratio of GMAB?
GMAB has a P/E ratio of approximately 27.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for GMAB?
GMAB has recorded a 52-week high of $35.43 and a low of $23.62.
